Effects of inflammatory disease on plasma oxprenolol concentrations.
- 25 August 1979
- Vol. 2 (6188) , 465-468
- https://doi.org/10.1136/bmj.2.6188.465
Abstract
When single oral doses of oxprenolol were given to three healthy subjects on three separate occasions under standardised conditions the plasma concentration-time curves for each subject were closely similar. In two of the subjects, however, a mild illness led to a dramatic, temporary increase in the peak plasma concentration and area under the plasma concentration-time curve (AUC). This effect of inflammatory disease was confirmed by comparing a group of patients with an erythrocyte sedimentation rate (ESR) of over 20 mm in the first hour with a group whose ESR was below this value. The mean peak plasma concentration and AUC were significantly higher in the group with a raised ESR. This may be related to altered concentrations of one of the acute-phase proteins. Thus it is concluded that plasma oxprenolol concentrations are raised in inflammatory disease, but further work is needed to determine the mechanism of this increase.Keywords
This publication has 6 references indexed in Scilit:
- DRUG BINDING TO α1-GLYCOPROTEINThe Lancet, 1979
- Increased Plasma Protein Binding of Propranolol and Chlorpromazine Mediated by Disease-Induced Elevations of Plasma α1Acid GlycoproteinNew England Journal of Medicine, 1978
- Pharmacokinetics of oxprenolol in normal subjectsClinical Pharmacology & Therapeutics, 1976
- A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.British Journal of Clinical Pharmacology, 1976
- Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in manEuropean Journal of Clinical Pharmacology, 1975
- The Metabolites of Oxprenolol (Trasicor®) in manXenobiotica, 1974